The study is published in TheJournal of the American Medical Association.
Less than half of the heart patients in the study with stable disease were taking antiplatelet drugs, statins, and beta-blockers before receiving stents or balloon angioplasty to open clogged blood vessels.
About a third of the patients weren’t prescribed the drugs after having the procedures.
Researchers found little difference in use of the drugs before and after the publication of a landmark 2007 study, known as COURAGE, which found that stents and angioplasty offered no survival advantage over preventive drug treatments alone in patients with stable coronary artery disease.
The study demonstrated the value of optimal drug management in these patients with a low risk for heart attacks and death. But its impact on clinical practice has been minimal, study researcher William B. Borden, MD, of Cornell University’s Weill Cornell Medical College, tells WebMD.
“When COURAGE was published it received a great deal of coverage in the medical and public press, so it was surprising to find that it did not influence practice patterns much,” Borden tells WebMD.
Borden and colleagues analyzed data from a national registry of patients with stable coronary artery disease treated with stents or balloon angioplasty between September 2005 and June 2009.
The analysis compared treatment with aspirin or another antiplatelet drug, beta-blockers, and cholesterol-lowering statins before and after the publication of the COURAGE trial and before and after hospital discharge following the percutaneous coronary intervention (PCI) procedures stenting or angioplasty.
Just over a third (37%) of the more than 460,000 patients included in the analysis were treated with PCI procedures before the COURAGE findings were made public.
Prior to the trial’s publication, around 43% of patients were on the drugs before having the interventional treatments. After its publication, around 45% of patients were taking the drugs before PCI.
After undergoing an interventional treatment, about 63% of patients were prescribed the drugs pre-COURAGE, compared to 66% of patients after the study’s publication.
“These findings suggest a significant opportunity for improvement and a limited effect of an expensive, highly publicized clinical trial on routine clinical practice,” Borden and colleagues write.